Anavex Life Sciences Corp.'s stock rises 50% as EMA reviews Alzheimer's drug blarcamesine. Click for my updated look at AVXL stock and why I have upgraded it.

New EU regulations aim to speed up health technology assessments (HTAs), but the pharma industry raises logistical concerns.

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...

Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be ...

H.C. Wainwright analyst raised the price target on Ocugen, Inc. (NASDAQ:OCGN) to $8.00, up from the previous $7.00, while maintaining a Buy rating on the stock. Currently trading at $0.66, the stock ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

Bishop asked about upcoming events. Missling outlined the anticipated schizophrenia trial readout for ANAVEX 3-71 in the first half of 2025, the detailed ATTENTION-AD data presentation in April, and ...

EC has granted marketing authorisation to BridgeBio Pharma’s acoramidis under the Beyonttra brand name for treating ATTR-CM.

Boca Raton, Florida Wednesday, February 12, 2025, 16:00 Hrs [IST] ...

GOMEKLI™ is an oral, small molecule MEK inhibitor approved in the United States for the treatment of adult and pediatric ...